Manufacturing Hold Times for Dietary Supplements: Why Delays Between Blending and Filling Matter

The blend is complete, but the capsule line is unavailable. The powder waits overnight. Is it still the same production intermediate that was approved at the end of blending?

Maybe—but elapsed time alone cannot answer the question. The formula, container, headspace, temperature, humidity, light, vibration, handling, and next process step determine whether a hold is routine or a quality risk.

Quick Answer

A manufacturing hold time is the controlled period during which a component, blend, intermediate, bulk dosage form, or packaged product waits before the next operation. There is no universal maximum hold time for every dietary supplement.

The manufacturer should define the hold stage, container, environmental conditions, time limit, identification, sampling, release status, and action for an unplanned extension. Brands should understand which product attributes can change during that interval and who decides whether production may continue.

What Is a Manufacturing Hold Time?

Hold time is the elapsed time between defined manufacturing events, such as:

• dispensing and blending;

• preblend and final blend;

• blending and encapsulation;

• blending and tablet compression;

• compression and coating;

• gummy depositing and demolding or conditioning;

• bulk softgel production and retail packaging;

• liquid compounding and filling; or

• filling and final packaging or QA release.

The clock needs a defined start and stop. “Held for one day” is ambiguous if one team starts the clock at blend discharge and another starts it after sampling.

Why a Delay Can Change an In-Process Batch

Powders can segregate

Differences in particle size, density, shape, and flow can cause a blend to separate during discharge, vibration, transport, settling, or hopper feeding. A homogeneous blend at the blender does not guarantee uniform delivery after repeated transfers.

Buyer consequence: first, middle, and last finished units may not match if the hold and transfer strategy is not controlled.

Hygroscopic materials can gain moisture

Powders containing salts, acids, sugars, fibers, botanical extracts, or other hygroscopic ingredients can absorb environmental moisture. The result may be caking, reduced flow, altered water activity, flavor change, capsule-fill variation, or compression problems.

Buyer consequence: the batch may slow down, produce more rejects, or require investigation before filling.

Volatile material can be lost

Flavors, aromas, solvents, and other volatile components may change during an open or poorly sealed hold. Headspace and repeated container opening can matter.

Buyer consequence: the final product may not match the approved sensory sample.

Oxygen and light can affect sensitive ingredients

Oils, flavors, colors, vitamins, botanicals, and other susceptible ingredients may oxidize or degrade. The actual risk depends on the matrix, exposure, temperature, package, and time.

Buyer consequence: a delay can become a stability question, not only a scheduling question.

In-process texture can continue to change

Gummies, soft chews, granulations, coated tablets, and other intermediates may continue to equilibrate, dry, crystallize, cure, or exchange moisture.

Buyer consequence: resuming the process at a different point in that physical transition can change depositing, demolding, coating, hardness, stickiness, or packaging behavior.

Microbiological risk can change

Wet or water-supporting intermediates may require tighter time and environmental controls than dry, low-water-activity blends. Sanitation status, temperature, pH, water activity, and exposure all influence the risk.

Buyer consequence: a hold cannot be extended from an operations spreadsheet alone; quality and food-safety considerations may control the decision.

Planned Hold vs. Unplanned Interruption

The Hold Container Is Part of the Process

A bulk liner, drum, tote, bin, tank, or tray is not neutral. The container affects:

• moisture and oxygen ingress;

• light exposure;

• headspace;

• electrostatic behavior;

• powder consolidation;

• segregation during transport;

• cleaning and contamination control;

• seal integrity;

• sampling access; and

• traceability.

Under 21 CFR 111.460, in-process material must be identified and held under conditions that protect against mix-up, contamination, and deterioration, including appropriate temperature, humidity, and light conditions.

Buyer action: ask how the intermediate is held, not only how long.

What a Hold-Time Definition Should Include

A named material stage

Specify whether the material is a premix, final blend, tablet core, coated tablet, bulk capsule, gummy, liquid bulk, or finished packaged product.

Start and stop events

Examples include “end of final blending to start of encapsulation” or “completion of liquid compounding to completion of filling.”

Approved container and closure

State liner type, container, closure status, fill level if relevant, and rules for reopening or transfer.

Environmental conditions

Define applicable temperature, humidity, light, sanitation, or other controls. Avoid vague phrases such as “room conditions” unless the operating range is controlled and documented.

Time limit and rationale

The limit may be supported by product knowledge, development studies, historical data, risk assessment, or a specific hold-time study. The evidence should match the actual material and conditions.

Sampling or checks before restart

Depending on risk, restart may require visual inspection, flow or moisture checks, blend sampling, mixing, filtration, temperature confirmation, microbiological review, or other actions.

Extension and deviation rule

Define who may approve continued processing, what evidence is reviewed, and when the material must be rejected or otherwise dispositioned.

A Seven-Step Hold-Time Risk Review

Step 1: Map every wait in the process

Include routine overnight holds, weekend holds, laboratory waits, equipment queues, coating delays, and bulk-storage periods. Hidden waiting time is still process time.

Step 2: Identify the material's failure modes

Review segregation, moisture gain, oxidation, volatility, microbial growth, settling, crystallization, texture, and cleanability.

Step 3: Define the real holding conditions

Record container, seal, headspace, room, temperature, humidity, light, movement, and access frequency.

Step 4: Select meaningful attributes

The right assessment might involve appearance, odor, moisture, water activity, flow, bulk density, assay, uniformity, microbial quality, viscosity, pH, texture, or another product-specific attribute.

Step 5: Establish the planned limit

Use evidence relevant to the formula, intermediate, process, and container. Do not borrow a time limit from another product merely because both are powders or gummies.

Step 6: Verify restart behavior

The material must still feed, fill, compress, deposit, coat, or package consistently after the hold. Laboratory results alone may not reveal an operational failure.

Step 7: Control changes

Reassess after changes to supplier, grade, formula, scale, container, room, process sequence, equipment, package, or schedule.

What Happens After an Unplanned Hold?

The quality decision should be based on evidence, not urgency.

1. Stop and protect the material.

2. Confirm identity, lot, process stage, and status.

3. Reconstruct the timeline and environmental exposure.

4. Review why the interruption occurred.

5. Compare actual conditions with approved limits.

6. Assess contamination, segregation, deterioration, and process-performance risks.

7. Perform justified checks or testing.

8. Document the material review and disposition decision.

9. Define restart instructions and any added monitoring.

10. Evaluate whether other batches or procedures are affected.

Passing one test does not automatically close every risk. For example, a moisture result may pass while segregation or flavor loss remains unresolved.

Brand Scheduling Decisions That Affect Hold Risk

Late label approval, delayed package delivery, formula changes, incomplete artwork, and last-minute order changes can create avoidable waiting time. A brand may view these as commercial delays, but production may need to hold a blend or finished bulk under controlled conditions.

Before scheduling, lock:

• formula and ingredient status;

• sample approval;

• packaging components;

• label and artwork approval;

• testing plan;

• batch size;

• line sequence; and

• release and shipping requirements.

B2B Procurement Checklist

• Complete process map and every expected hold point.

• Defined material stage for each hold.

• Start and stop events.

• Approved bulk container and closure.

• Temperature, humidity, light, and sanitation conditions.

• Routine maximum time and technical basis.

• Reopening, transfer, and movement rules.

• Sampling and restart checks.

• Deviation and extension process.

• Finished-product and downstream performance impact.

• Brand approval responsibilities.

• Production, packaging, testing, and launch schedule.

Frequently Asked Questions

Is there a legal maximum hold time for all dietary supplement blends?

No universal number applies to every formula and stage. 21 CFR Part 111 requires controlled manufacturing and holding conditions, while the manufacturer must define suitable procedures for the actual product and process.

Can a dry powder blend wait overnight?

Possibly, if the approved process supports that hold under defined conditions. Formula sensitivity, container, humidity, segregation, sanitation, and restart performance still need review.

Does a sealed drum eliminate hold-time risk?

No. It may reduce environmental exposure, but headspace, liner barrier, prior exposure, settling, segregation, container condition, and reopening still matter.

Should a blend be remixed after a long hold?

Not automatically. Remixing can improve distribution in one situation and create segregation or over-lubrication in another. Follow a justified, product-specific restart instruction.

What is the difference between hold time and shelf life?

Hold time applies to an in-process or bulk stage before the next manufacturing operation. Shelf life applies to the finished product under its defined package and storage conditions.

Can finished-product testing prove an extended hold was acceptable?

It can provide evidence for selected attributes, but may not address every risk or explain process performance. The investigation should cover the actual exposure and failure modes.

Who approves an unplanned hold extension?

The manufacturer's controlled quality procedures should assign the decision. The quality agreement should also clarify when the brand is notified or asked to approve a commercial change.

What should a brand send for a hold-time review?

Send the formula, process flow, dosage form, intermediate stage, proposed container, environmental conditions, package, schedule, market, forecast, and launch timing. Hold limits, tests, equipment, MOQ, and lead time require project confirmation.

Key Takeaways

• Hold time is a controlled process interval, not empty calendar time.

• The formula, material stage, container, environment, movement, and next operation define the risk.

• No single maximum time fits every dietary supplement.

• A sealed container reduces some exposures but does not solve segregation, history, or restart risks.

• Unplanned extensions require a documented, evidence-based disposition.

• Brand approvals and package readiness can affect production hold risk.

Discuss a Manufacturing Hold-Time Review

Send Aidacru your formula, dosage form, process flow, expected hold points, intermediate container, package, target market, forecast, and launch schedule. The review can identify open process, environmental, sampling, testing, scheduling, and quotation questions before bulk production.

Technical References

• 21 CFR 111.355–111.365, Dietary Supplement Manufacturing Operations: https://www.govinfo.gov/content/pkg/CFR-2025-title21-vol2/pdf/CFR-2025-title21-vol2-sec111-365.pdf

• 21 CFR 111.455–111.460, Holding Components and In-Process Material: https://www.govinfo.gov/content/pkg/CFR-2016-title21-vol2/pdf/CFR-2016-title21-vol2-sec111-475.pdf

• U.S. FDA, Dietary Supplement CGMP Small Entity Compliance Guide: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/small-entity-compliance-guide-current-good-manufacturing-practice-manufacturing-packaging-labeling

• Aidacru, Dietary Supplement Manufacturing Process: https://www.aidacruhealth.com/en/private-label-supplement-manufacturing-process-n6151.html